VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
26.04.2024 09:00
Medigene AG
26.04.2024 08:00
Fast Finance 24 Holding AG
26.04.2024 07:44
POLYTEC HOLDING AG
EUROPA NACHRICHTEN
ADHOC
Do, 15.10.2020 22:00
pta20201015043
Business news for the stock market
Medigene AG: Three Medigene poster presentations at SITC Annual MeetingPlanegg/Martinsried (pta043/15.10.2020/22:00) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present three posters at the Society for Immunotherapy of Cancer 35th Annual Meeting (SITC 2020) being held virtually on 9-14 November 2020. The three poster presentations relate to work on Medigene's clinical and preclinical programs including production feasibility results from the dendritic cell (DC) vaccine Phase I/II clinical trial completed earlier this year, as well as further research describing the activity of the company's PD1-41BB switch receptor and the CD8 co-receptor independence of the company's T cell receptor specific for MAGE-A4. Full-length abstracts will be published online on 9 November 2020 at 8:00 am EST. Posters will be available in the Virtual Poster Hall on 11-14 November 2020 from 9:00 am - 5:00 pm EST.
Poster details
#
271 Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial
#
614 Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation
--- end of press release ---
About Medigene
About Medigene's TCR-Ts
About Medigene's DC vaccines
Dendritic cells (DC) can take up antigens, process them and present peptides on their surface in a form that can induce antigen-specific T cells to mature and proliferate. In this way, T cells recognize and eliminate tumor cells which bear the same antigen peptide on their surface. Dendritic cells can also induce natural killer cells (NK cells) to attack tumor cells. The scientific team of Medigene has developed new, fast and efficient methods for generating autologous (patient-specific) mature dendritic cells which have the relevant characteristics to generate very strong T cell and NK cell immune responses. The dendritic cells can be loaded with various tumor antigens to treat different forms of cancer. Since an immune response builds up over the total time of administration of the DC vaccine, this form of therapy is particularly designed for patients who suffer from a tumor disease which has been reduced to such an extent by chemotherapy that the prevention of the recurrence of the tumor disease is the main goal.
About Medigene's PD1-41BB switch receptor
The 4-1BB co-stimulatory signaling pathway: Effective T cell immune responses to antigens typically require costimulatory signals to be received alongside the primary antigenic stimulation via the T cell receptor (TCR). The intracellular signaling domains of the 4-1BB protein offer a well-characterized pathway to positively enhance T cell responses. Medigene's PD1-41BB switch receptor takes advantage of the binding of PD-1 on the T cells to PD-L1 on tumors. In the switch receptor, the inhibitory signaling domain of PD-1 has been substituted with the activating signaling domain of 4-1BB. As a result, the switch receptor then delivers an activating signal to the TCR-T cells (not the usual inhibitory signal of PD-1). This enables the PD1-41BB-modified TCR-T cells to proliferate strongly in the presence of PD-L1-positive tumor cells and to mediate greater killing of tumor cells upon repeated exposure. Additionally, signals mediated through the switch receptor also enhance metabolic fitness of TCR-T cells, enabling better function in conditions of low levels of glucose or high levels of the immunosuppressive factor TGFß, two conditions that are characteristic of strongly hostile tumor microenvironments. This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
LifeSci Advisors
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list. (Ende)
PRESSETEXT.TV
Walter Oblin sieht Post auf Wachstumskurs 18.04.2023 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|